Nature Reviews Genetics 17, 197 (2016). doi:10.1038/nrg.2016.12
Authors: Matthew R. Nelson, Toby Johnson, Liling Warren, Arlene R. Hughes, Stephanie L. Chissoe, Chun-Fang Xu & Dawn M. Waterworth
Lack of sufficient efficacy is the most common cause of attrition in late-phase drug development. It has long been envisioned that genetics could drive stratified drug development by identifying those patient subgroups that are most likely to respond. However, this vision has not been realized
from Genetics via xlomafota13 on Inoreader http://ift.tt/1Xun7hV
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.